Keros Therapeutics

Keros Therapeutics

  • Founded: 2015
  • Location: Lexington, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: Myelodysplastic syndromes
  • Drug types: ONC, HEM, MUS
  • Lead product: KER-050
  • Product link:
  • Funding: $110M IPO Apr 2020; $23M B Jan 2019; $11M A 2016
  • Investors: Pontifax, Arkin Bio Ventures,¬†Partners Innovation Fund, Medison Pharma, Global Health Sciences Fund

job board

Short description:

Rare Muscle Disorders

Drug notes:

Also Clin2 myelofibrosis; KER-047 Clin2 iron deficiency anemia, Clin1 iron deficiency anemia in MDS & MF; KER-012 Clin1PAH; undisclosed Clin0 musculoskeletal conditions

Long description:

Contact us to add description.


© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy